90Y-Pentixather

**90Y-Pentixather** is a targeted radiopharmaceutical therapy under investigation for the treatment of cancers overexpressing the chemokine receptor **CXCR4**. It is a therapeutic analogue of the diagnostic agent 68Ga-Pentixafor, designed to deliver **yttrium-90**–emitted beta radiation directly to tumor cells through a targeting ligand (Pentixather) selective for **CXCR4**. This approach enables precise microdosimetry and has shown promising preliminary results in patients with multiple myeloma, central nervous system lymphoma, T-cell lymphoma, and acute myeloid leukemia. Early clinical studies (Phase 1/2) have highlighted its potential superiority over alternative targeted radiotherapies, including 177Lu-Pentixather, especially in multiple myeloma. Ongoing trials are further evaluating its safety, optimal dose, efficacy, and possible applications in other CXCR4-positive malignancies[1][3][5][7][9].

Brand names

PentixaTher

Other names

PentixatherYttrium-90 AnditixafortideYttrium90 AnditixafortideYttrium 90 Anditixafortide